FTC Orders Illumina to Divest Cancer Detection Test Maker GRAIL to Protect Competition in Life-Saving Technology Market
GRAIL makes non-invasive, early detection liquid biopsy tests that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing.
- GRAIL makes non-invasive, early detection liquid biopsy tests that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing.
- These tests could be used to detect multiple types of cancer, most of which are not screened for at all today.
- - Illumina has an enormous financial incentive to ensure that GRAIL wins the innovation race in the U.S. MCED market.
- Illumina stands to earn substantially more profit on the sale of GRAIL tests than it does by supporting rival test developers.